These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

65 related items for PubMed ID: 22311517

  • 1. Responses of urinary N-telopeptide and renal calcium handling to PTH infusion after treatment with estrogen, raloxifene, and tamoxifen.
    Kulak CA, Baz-Hecht M, Nieves J, Shen V, Lindsay R, Cosman F.
    Calcif Tissue Int; 2012 Apr; 90(4):263-71. PubMed ID: 22311517
    [Abstract] [Full Text] [Related]

  • 2. Effects of gonadal steroid suppression on skeletal sensitivity to parathyroid hormone in men.
    Leder BZ, Smith MR, Fallon MA, Lee ML, Finkelstein JS.
    J Clin Endocrinol Metab; 2001 Feb; 86(2):511-6. PubMed ID: 11158001
    [Abstract] [Full Text] [Related]

  • 3. Skeletal effects of parathyroid hormone infusion in ovariectomized rats with or without estrogen repletion.
    Shen V, Birchman R, Wu DD, Lindsay R.
    J Bone Miner Res; 2000 Apr; 15(4):740-6. PubMed ID: 10780865
    [Abstract] [Full Text] [Related]

  • 4. Effects of raloxifene, a selective estrogen receptor modulator, on bone turnover markers and serum sex steroid and lipid levels in elderly men.
    Doran PM, Riggs BL, Atkinson EJ, Khosla S.
    J Bone Miner Res; 2001 Nov; 16(11):2118-25. PubMed ID: 11697809
    [Abstract] [Full Text] [Related]

  • 5. A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women.
    Reid IR, Eastell R, Fogelman I, Adachi JD, Rosen A, Netelenbos C, Watts NB, Seeman E, Ciaccia AV, Draper MW.
    Arch Intern Med; 2004 Apr 26; 164(8):871-9. PubMed ID: 15111373
    [Abstract] [Full Text] [Related]

  • 6. Role of the interleukin-6/interleukin-6 soluble receptor cytokine system in mediating increased skeletal sensitivity to parathyroid hormone in perimenopausal women.
    Insogna K, Mitnick M, Pascarella J, Nakchbandi I, Grey A, Masiukiewicz U.
    J Bone Miner Res; 2002 Nov 26; 17 Suppl 2():N108-16. PubMed ID: 12412787
    [Abstract] [Full Text] [Related]

  • 7. Evidence that the IL-6/IL-6 soluble receptor cytokine system plays a role in the increased skeletal sensitivity to PTH in estrogen-deficient women.
    Masiukiewicz US, Mitnick M, Gulanski BI, Insogna KL.
    J Clin Endocrinol Metab; 2002 Jun 26; 87(6):2892-8. PubMed ID: 12050269
    [Abstract] [Full Text] [Related]

  • 8. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.
    Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, Glass EV, Myers SL, Krege JH.
    J Bone Miner Res; 2005 Nov 26; 20(11):1905-11. PubMed ID: 16234962
    [Abstract] [Full Text] [Related]

  • 9. Effect of zoledronic acid compared with raloxifene on bone turnover markers in postmenopausal women with low bone density.
    Bachmann G, Kriegman A, Gonçalves J, Kianifard F, Warren M, Simon JA.
    Menopause; 2011 Aug 26; 18(8):851-6. PubMed ID: 21796066
    [Abstract] [Full Text] [Related]

  • 10. Role of parathyroid hormone in mediating nocturnal and age-related increases in bone resorption.
    Ledger GA, Burritt MF, Kao PC, O'Fallon WM, Riggs BL, Khosla S.
    J Clin Endocrinol Metab; 1995 Nov 26; 80(11):3304-10. PubMed ID: 7593443
    [Abstract] [Full Text] [Related]

  • 11. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
    Ozmen B, Kirmaz C, Aydin K, Kafesciler SO, Guclu F, Hekimsoy Z.
    Eur Cytokine Netw; 2007 Sep 26; 18(3):148-53. PubMed ID: 17823083
    [Abstract] [Full Text] [Related]

  • 12. Effects of endogenous estrogen on renal calcium and phosphate handling in elderly women.
    Dick IM, Devine A, Beilby J, Prince RL.
    Am J Physiol Endocrinol Metab; 2005 Feb 26; 288(2):E430-5. PubMed ID: 15466921
    [Abstract] [Full Text] [Related]

  • 13. Marked reduction of bone turnover by alendronate attenuates the acute response of bone resorption marker to endogenous parathyroid hormone.
    Zikan V, Stepan JJ.
    Bone; 2009 Apr 26; 44(4):634-8. PubMed ID: 19150421
    [Abstract] [Full Text] [Related]

  • 14. Effects of the circadian variation in serum cortisol on markers of bone turnover and calcium homeostasis in normal postmenopausal women.
    Heshmati HM, Riggs BL, Burritt MF, McAlister CA, Wollan PC, Khosla S.
    J Clin Endocrinol Metab; 1998 Mar 26; 83(3):751-6. PubMed ID: 9506720
    [Abstract] [Full Text] [Related]

  • 15. Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk.
    Reginster JY, Sarkar S, Zegels B, Henrotin Y, Bruyere O, Agnusdei D, Collette J.
    Bone; 2004 Feb 26; 34(2):344-51. PubMed ID: 14962813
    [Abstract] [Full Text] [Related]

  • 16. Calciotropic hormones and bone markers in the elderly.
    Gallagher JC, Kinyamu HK, Fowler SE, Dawson-Hughes B, Dalsky GP, Sherman SS.
    J Bone Miner Res; 1998 Mar 26; 13(3):475-82. PubMed ID: 9525348
    [Abstract] [Full Text] [Related]

  • 17. Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women.
    Cosman F, Nieves J, Woelfert L, Shen V, Lindsay R.
    J Bone Miner Res; 1998 Jun 26; 13(6):1051-5. PubMed ID: 9626638
    [Abstract] [Full Text] [Related]

  • 18. Resistance to bone resorbing effects of PTH in black women.
    Cosman F, Morgan DC, Nieves JW, Shen V, Luckey MM, Dempster DW, Lindsay R, Parisien M.
    J Bone Miner Res; 1997 Jun 26; 12(6):958-66. PubMed ID: 9169356
    [Abstract] [Full Text] [Related]

  • 19. Different effects of raloxifene and estrogen on interleukin-1beta and interleukin-1 receptor antagonist production using in vitro and ex vivo studies.
    Rogers A, Clowes JA, Pereda CA, Eastell R.
    Bone; 2007 Jan 26; 40(1):105-10. PubMed ID: 16934544
    [Abstract] [Full Text] [Related]

  • 20. The effect of raloxifene on markers of bone turnover in older women living in long-term care facilities.
    Hansdóttir H, Franzson L, Prestwood K, Sigurdsson G.
    J Am Geriatr Soc; 2004 May 26; 52(5):779-83. PubMed ID: 15086661
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.